Strategies for Managing Solid Form Transformation Risk in Drug Product

Area of Science:

• Pharmaceutical Sciences
• Solid-State Chemistry
• Drug Development

Background:

• The International Conference of Harmonization (ICH) Q6A guidance offers high-level recommendations for monitoring and controlling solid-state form transformation.
• Current guidance lacks detailed assessments for transformation risk and bioavailability impact severity throughout drug development.

Purpose of the Study:

• To provide comprehensive Chemistry Manufacturing and Controls (CMC) and regulatory strategies for managing drug substance and product solid-state form transformation risks.
• To offer practical workflows for risk assessment, analytical detection, and biopharmaceutical evaluation of form transformation.

Main Methods:

• Review of ICH Q6A decision trees related to solid-state form transformation.
• Development of practical workflows for risk assessment and management.
• Integration of analytical and biopharmaceutical tools for transformation analysis and bioavailability impact assessment.
• Case study analysis to demonstrate workflow application.

Main Results:

• Established comprehensive CMC and regulatory strategies for managing solid-state form transformation.
• Outlined practical workflows for risk assessment, including analytical and biopharmaceutical considerations.
• Demonstrated the utility of the proposed workflow through case studies.

Conclusions:

• Effective management of solid-state form transformation requires integrated CMC and regulatory strategies beyond current high-level guidance.
• The proposed workflows and tools aid in assessing transformation risk, detecting changes, and understanding bioavailability impacts.
• Proactive management of form transformation is crucial for ensuring drug product quality and clinical relevance.